Literature DB >> 2358969

Clinical significance of nuclear DNA content in pancreatic carcinoma.

K A Alanen1, H Joensuu, P J Klemi, T J Nevalainen.   

Abstract

The nuclear DNA content of 62 pancreatic adenocarcinomas was analysed by flow cytometry from paraffin-embedded material. Radical surgery could be performed in 12 of the 24 cases with diploid carcinoma, but only in 3 of the 38 cases with a non-diploid tumour (P = 0.0002); the radically resected carcinomas also had a lower fraction of cells in the S-phase (P = 0.009). Non-diploid nuclear DNA content (38 cases, 61 per cent) was associated with advanced stage (P = 0.002), poor histological differentiation (grade II or III, P = 0.004), and primary tumour site in the body or the tail as compared with the head (P = 0.01). The median survival time of the patients with diploid carcinoma was 13 +/- 3 (SE) months, and that of the patients with non-diploid carcinoma 3 +/- 1 months (P = 0.0001). The DNA index with the cutoff value 1.4 was a slightly more powerful prognostic factor than DNA ploidy, and it was the most important independent prognostic factor in Cox's multivariate analysis (P less than 0.001) followed by histological grade (P less than 0.03). We conclude that diploid pancreatic carcinomas are associated with a longer survival than the non-diploid ones, and that radically operable carcinomas form a special subgroup with frequent diploidy and less aggressive biological behaviour.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2358969     DOI: 10.1002/path.1711600407

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  Implications of malignant-cell DNA content for treatment of patients with pancreatic cancer.

Authors:  A L Warshaw
Journal:  Ann Surg       Date:  1991-12       Impact factor: 12.969

2.  DNA ploidy and cell-cycle analysis in pancreatic and ampullary carcinoma: flow cytometric study of formalin-fixed paraffin-embedded tissue.

Authors:  K A Alanen; H Joensuu; P J Klemi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Combined use of nuclear morphometry and DNA ploidy as prognostic indicators in nonresectable adenocarcinoma of the pancreas.

Authors:  S Linder; J Lindholm; U Falkmer; M Blåsjö; P Sundelin; A von Rosen
Journal:  Int J Pancreatol       Date:  1995-12

4.  Expression of argyrophilic nucleolar organizer regions in ductal adenocarcinoma of the pancreas and its relationship to prognosis.

Authors:  T Ohta; T Nagakawa; Y Tsukioka; K Mori; T Takeda; M Kayahara; K Ueno; L Fonseca; I Miyazaki; T Terada
Journal:  Int J Pancreatol       Date:  1993-06

5.  Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.

Authors:  Nikolas Tsavaris; Nicolaos Kavantzas; Kostantinos Tsigritis; Ioannis D Xynos; Nikitas Papadoniou; Andreas Lazaris; Christos Kosmas; George Agrogiannis; Anna Dokou; Evangelos Felekouras; Efstathios Antoniou; Aris Polyzos; John Sarantonis; Heracles Tsipras; Gavrilos Karatzas; Alexandros Papalambros; Efstratios S Patsouris
Journal:  BMC Cancer       Date:  2009-07-31       Impact factor: 4.430

6.  Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas.

Authors:  T Ohta; M Yamamoto; M Numata; S Iseki; Y Tsukioka; T Miyashita; M Kayahara; T Nagakawa; I Miyazaki; K Nishikawa; Y Yoshitake
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.